UK markets closed

Qualigen Therapeutics, Inc. (7R9.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
0.1390-0.0140 (-9.15%)
At close: 08:05AM CEST
Full screen
Previous close0.1530
Open0.1390
Bid0.1630 x N/A
Ask0.2080 x N/A
Day's range0.1390 - 0.1390
52-week range0.1390 - 1.0960
Volume200
Avg. volume172
Market cap1.169M
Beta (5Y monthly)0.13
PE ratio (TTM)N/A
EPS (TTM)-2.2900
Earnings date17 Jun 2024 - 23 Jun 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination

    CARLSBAD, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), announced today that on May 23, 2024, it received written notice (the “Delist Notice”) from The Nasdaq Stock Market (“Nasdaq”) indicating the Company’s continued non-compliance with the minimum bid price requirement, pursuant to Listing Rule 5550(b)(2). As previously reported, on November 20, 2023, the Company received a letter (the “Bid Price Deficiency Notice”) from Nasda

  • GlobeNewswire

    Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™

    JUPITER, FL, April 16, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme, Inc. ("Marizyme", OTCQB: MRZM) announces today a Co-Development Agreement (the “Agreement”) with Qualigen Therapeutics, Inc. (“Qualigen”) (NASDAQ: QLGN) to advance the commercialization of Marizyme’s first-in-class FDA cleared product, DuraGraft™. DuraGraft™ was granted a De Novo – FDA Clearance on October 4, 2023, from the U.S. Food and Drug Administration (FDA). DuraGraft™ is labeled for use as a vascular conduit sol

  • GlobeNewswire

    Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting

    Poster Includes Preclinical Data on Novel Direct Pan-RAS Inhibitors CARLSBAD, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN) today announces a poster presentation on its preclinical Novel Direct Pan-RAS Inhibitors was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 held April 5 – 10 in San Diego, California. “We continue to see cancers developing resistance to current clinical agents that tar